產(chǎn)品編號 | bs-7913R |
英文名稱 | Rabbit Anti-phospho-LATS1+LATS2 (Thr1079 +Thr1041) antibody |
中文名稱 | 磷酸化腫瘤抑制基因LATS1/LATS2抗體 |
別 名 | LATS1 +LATS2 (phospho T1079 + T1041); Serine/threonine protein kinase LATS2; KPM; Large tumor supressor, homolog 1; LATS, large tumor suppressor, homolog 1 (Drosophila); LATS, large tumor suppressor, homolog 2 (Drosophila); LATS1 +LATS2 (phospho T1079 + T1041); p-LATS1 +LATS2(Thr1079 +Thr1041); RGD1564085; Serine/threonine protein kinase LATS1; WARTS; WARTS protein kinase; wts; 4932411G09Rik; AV277261; AW208599; AW228608; FLJ13161; LATS1_HUMAN. |
Specific References (10) | bs-7913R has been referenced in 10 publications.
|
|
產(chǎn)品類型 | 磷酸化抗體 |
研究領(lǐng)域 | 腫瘤 細胞生物 信號轉(zhuǎn)導 細胞周期蛋白 激酶和磷酸酶 |
抗體來源 | Rabbit |
克隆類型 | Polyclonal |
交叉反應(yīng) | Human,Mouse,Rabbit (predicted: Rat,Pig,Cow,Chicken,Dog,Horse) |
產(chǎn)品應(yīng)用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
理論分子量 | 124kDa |
細胞定位 | 細胞漿 |
性 狀 | Liquid |
濃 度 | 1mg/ml |
免 疫 原 | KLH conjugated synthesised phosphopeptide derived from human LATS1 around the phosphorylation site of Thr1079: EF(P-T)FR |
亞 型 | IgG |
純化方法 | affinity purified by Protein A |
緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
PubMed | PubMed |
產(chǎn)品介紹 |
Negative regulator of YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein MST1/MST2, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. Acts as a tumor suppressor which plays a critical role in centrosome duplication, maintenance of mitotic fidelity and genomic stability. Negatively regulates G1/S transition by down-regulating cyclin E/CDK2 kinase activity. Negative regulator of the androgen receptor. Function: Negative regulator of YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS1 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. Acts as a tumor suppressor which plays a critical role in maintenance of ploidy through its actions in both mitotic progression and the G1 tetraploidy checkpoint. Negatively regulates G2/M transition by down-regulating CDK1 kinase activity. Involved in the control of p53 expression. Affects cytokinesis by regulating actin polymerization through negative modulation of LIMK1. May also play a role in endocrine function. Subunit: Complexes with CDK1 in early mitosis. LATS1-associated CDK1 has no mitotic cyclin partner and no apparent kinase activity. Binds phosphorylated ZYX, locating this protein to the mitotic spindle and suggesting a role for actin regulatory proteins during mitosis. Binds to and colocalizes with LIMK1 at the actomyosin contractile ring during cytokinesis. Interacts (via PPxY motif 2) with YAP1 (via WW domains). Interacts with MOB1A and MOB1B. Interacts with LIMD1, WTIP and AJUBA. Subcellular Location: Cytoplasm, cytoskeleton, centrosome. Note=Localizes to the centrosomes throughout interphase but migrates to the mitotic apparatus, including spindle pole bodies, mitotic spindle, and midbody, during mitosis. Tissue Specificity: Expressed in all adult tissues examined except for lung and kidney. Post-translational modifications: Autophosphorylated and phosphorylated during M-phase of the cell cycle. Phosphorylated by STK3/MST2 at Ser-909 and Thr-1079, which results in its activation. Phosphorylated upon DNA damage, probably by ATM or ATR. Phosphorylation at Ser-464 by NUAK1 and NUAK2 leads to decreased protein level and is required to regulate cellular senescence and cellular ploidy. Similarity: Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. Contains 1 AGC-kinase C-terminal domain. Contains 1 protein kinase domain. Contains 1 UBA domain. SWISS: O95835 Gene ID: 26524 Database links: Entrez Gene: 26524 Human Entrez Gene: 9113 Human Entrez Gene: 16798 Mouse Entrez Gene: 50523 Mouse Omim: 603473 Human Omim: 604861 Human SwissProt: O95835 Human SwissProt: Q9NRM7 Human SwissProt: Q7TSJ6 Mouse SwissProt: Q8BYR2 Mouse |
產(chǎn)品圖片 |
Sample:
Cerebrum (Mouse) Lysate at 40 ug
Primary: Anti-phospho-LATS1+LATS2 (Thr1079 +Thr1041) (bs-7913R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 124 kD
Observed band size: 124 kD
Sample:
Hela(Human) Cell Lysate at 30 ug
Primary: Anti-phospho-LATS1+LATS2 (Thr1079 +Thr1041) (bs-7913R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 124 kD
Observed band size: 124 kD
Paraformaldehyde-fixed, paraffin embedded (Mouse brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (phospho-LATS1+LATS2 (Thr1079 +Thr1041)) Polyclonal Antibody, Unconjugated (bs-7913R) at 1:500 overnight at 4°C, followed by a conjugated secondary (sp-0023) for 20 minutes and DAB staining.
|
1、抗體溶解方法 | |
2、抗體修復方式 | |
3、常用試劑的配制 | |
4、免疫組化操作步驟 | |
5、免疫組化問題解答 | |
6、Western Blotting 操作步驟 | |
7、Western Blotting 問題解答 | |
8、關(guān)于肽鏈的設(shè)計 | |
9、多肽的溶解與保存 | |
10、酶標抗體效價測定程序 | |